Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

N/A
2(66.7%)
Phase 1
1(33.3%)
3Total
N/A(2)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT04632303Not ApplicableActive Not Recruiting

Early Palliative Care for Patients With Advanced Pancreatic Cancer.

Role: lead

NCT05721846Phase 1Active Not Recruiting

Nivolumab With Ipilimumab Combined With TGFβ-15 Peptide Vaccine and Radiotherapy for Pancreatic Cancer

Role: lead

NCT06713525Not Yet Recruiting

Observational Copenhagen Pancreatic Cancer Study

Role: lead

NCT04611867Not ApplicableRecruiting

Study of PRO in Patients with Advanced Pancreatic or Biliary Tract Cancer (BetterEveryDay)

Role: lead

NCT03311776Recruiting

BIOmarkers in Patients With Pancreatic Cancer ("BIOPAC")

Role: lead

All 5 trials loaded